{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:44Z","timestamp":1787027024691,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Olaparib-induced anemia is a frequently occurring complication in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and is associated with a marked deterioration in patients\u2019 health-related quality of life. This study aimed to clarify patient-specific risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, retrospective, observational study enrolled consecutively presenting patients with advanced ovarian or breast cancer who received olaparib monotherapy as maintenance or palliative treatment between April 2018 and December 2020 at three participating medical institutions in Japan. The primary endpoint was patient-associated risk factors underlying the onset of grade \u22653 anemia from olaparib treatment initiation to 90 days after treatment. Receiver operating characteristic curves were constructed and univariable and multivariable logistic regression analyses were performed to evaluate the association between patient-associated risk factors and grade \u22653 anemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 113 patients evaluated in this study, 32.7% (\n                      <jats:italic>n<\/jats:italic>\n                      = 37) had grade \u22653 anemia. Multivariable logistic regression analysis revealed that low baseline red blood cell (RBC) count (&amp;lt;3.3 \u00d7 10\n                      <jats:sup>6<\/jats:sup>\n                      cells\/\u03bcL), low baseline hematocrit level (&amp;lt;35%), low baseline hemoglobin level (&amp;lt;11.6 g\/dL), and breast cancer susceptibility (\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      ) mutation were significantly associated with the onset of grade \u22653 anemia (adjusted odds ratio [OR], 3.39; 95% confidence interval [CI], 1.28\u20139.62;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.017, adjusted OR, 3.63; 95% CI, 1.28\u201311.64;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.021, adjusted OR, 3.89; 95% CI, 1.39\u201312.21;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.014, and adjusted OR, 4.09; 95% CI, 1.55\u201311.67;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.006, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our findings suggest that low baseline RBC count, low baseline hematocrit level, and low baseline hemoglobin level might be the patient-associated risk factors for severe anemia induced by olaparib monotherapy. Additionally,\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutation was suggested to be a patient-related risk factor for anemia regardless of severity. Therefore, applying these patient-associated risk factors would help classify and screen patients at risk of severe anemia.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2022.898150","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T04:11:55Z","timestamp":1664856715000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study"],"prefix":"10.3389","volume":"12","author":[{"given":"Ryota","family":"Tashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Mamishin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Yonemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Terakado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","unstructured":"Breast cancer. version 2.2022. NCCN clinical practice guidelines in oncology"},{"key":"B6","unstructured":"Ovarian Cancer\/Fallopian tube Cancer\/Primary peritoneal cancer. version 1.2022. NCCN clinical practice guidelines in oncology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.06.012","article-title":"Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials","volume":"141","author":"Ruiz-Schutz","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.202","article-title":"PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors","volume":"22","author":"Farr\u00e9s","year":"2015","journal-title":"Cell Death Differ"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/genes11121528","article-title":"Chromosome instability in fanconi anemia: From breaks to phenotypic consequences","volume":"11","author":"Garc\u00eda-de-Teresa","year":"2020","journal-title":"Genes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/genes11050585","article-title":"The FANC\/BRCA pathway releases replication blockades by eliminating DNA interstrand cross-links","volume":"11","author":"Renaudin","year":"2020","journal-title":"Genes"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2283-4","article-title":"Recent insights into the molecular basis of fanconi anemia: Genes, modifiers, and drivers","volume":"106","author":"Cheung","year":"2017","journal-title":"Int J Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/blood-2012-07-441212","article-title":"Regulation of multiple DNA repair pathways by the fanconi anemia protein SLX4","volume":"121","author":"Kim","year":"2013","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102837","article-title":"Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia","volume":"145","author":"Abdel-Razeq","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04780-7","article-title":"Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy","volume":"28","author":"Razzaghdoust","year":"2020","journal-title":"Support Care Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.770268","article-title":"Prognostic value of baseline medications plus neutrophil-to-lymphocyte ratio in the effectiveness of nivolumab and pembrolizumab in patients with advanced non-small-cell lung cancer: a retrospective study","volume":"11","author":"Ogiwara","year":"2021","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618570","article-title":"Absolute lymphocyte count predicts immune-related adverse events in patients with non-small-cell lung cancer treated with nivolumab monotherapy: a multicenter retrospective study","volume":"11","author":"Egami","year":"2021","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7150\/jca.53242","article-title":"Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study","volume":"12","author":"Egami","year":"2021","journal-title":"J Cancer"},{"key":"B20","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0"},{"key":"B21","unstructured":"Common criteria range of the Japan clinical oncology group (JCOG)"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198509844.001.0001","volume-title":"The statistical evaluation of medical tests for classification and prediction","author":"Pepe","year":"2003"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jclinepi.2010.11.012","article-title":"Performance of logistic regression modeling: Beyond the number of events per variable, the role of data structure","volume":"64","author":"Courvoisier","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0499-5","article-title":"Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population","volume":"58","author":"Hiratsuka","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.027","article-title":"Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy","volume":"23","author":"Chang","year":"2005","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21570","article-title":"Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review","volume":"106","author":"Lyman","year":"2005","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00169-1","article-title":"Predicting cancer-associated anemia in patients receiving nonplatinum chemotherapy: Results of a retrospective survey","volume":"37","author":"Coiffier","year":"2001","journal-title":"Eur J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.898150\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T06:50:22Z","timestamp":1701154222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.898150\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":30,"alternative-id":["10.3389\/fonc.2022.898150"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.898150","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"article-number":"898150"}}